EDG-5506 is an oral small molecule muscle stabilizer. EDG-5506 seeks to protect the muscle from injuries due to hypercontractal stress when dystrophin is absent or has reduced function. By helping to shield the muscle from damage and limit the muscle breakdown EDG-5506 may provide benefit to individuals living with Duchenne and Becker.
A Phase 2 study in Becker is actively recruiting. A Phase 2 study in Duchenne is actively recruiting. A Phase 2 study in Duchenne patients who previously received a gene therapy is not yet recruiting
This program is sponsored by Edgewise Therapeutics.
MAY 2023 | Webinar: Edgewise — A Novel Approach Designed to Protect Muscle in Becker (May 2023)PPMD was joined by Edgewise Therapeutics for a community webinar on May 3, 2023 to discuss the company’s novel approach designed to protect muscle in individuals living with Becker muscular dystrophy. |
OCTOBER 2022 | Webinar: Edgewise Therapeutics – A Novel Approach to Protect Muscle in Duchenne & Becker (October 2022)PPMD was joined by Edgewise Therapeutics for a community webinar on October 19, 2022. Edgewise’s Chief Scientific Officer and Chief Medical Officer discussed the clinical development program for EDG-5506, a myosin modulator, in Becker and Duchenne muscular dystrophies. The webinar also highlighted the mechanism of action, results from the ongoing open-label ARCH study in adults with Becker muscular dystrophy, and upcoming trials. |
JUNE 2021 | Edgewise Therapeutics at the PPMD 2021 Virtual Annual ConferencePre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library |
